BridgeBio Oncology Therapeutics, Inc. (BBOT) Free cash flow 2024–2025
BridgeBio Oncology Therapeutics, Inc. (BBOT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$114.5MFY2025 · since FY2024: -$55.1M → -$114.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$114.5M | -107.9% |
| FY2024 | -$55.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More BBOT financial trends
BBOT RevenueBBOT Net incomeBBOT Net marginBBOT Gross profitBBOT Gross marginBBOT Operating incomeBBOT Operating marginBBOT Operating cash flowBBOT Capital expendituresBBOT Return on equityBBOT Stock buybacksBBOT Dividends paidBBOT Total assetsBBOT Total liabilitiesBBOT Shareholders’ equityBBOT overview →